Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Serhat Gumrukcu manages a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. There are 2 pending office actions currently active for this entity. These actions represent the current legal hurdles the company faces in the biotech and pharma sectors. The presence of 2 pending office actions indicates a focused but active prosecution pipeline.
The 2 pending office actions are distributed across 2 distinct examiners and 2 distinct art units. This distribution shows that the company's technology is being reviewed by 2 different specialized divisions within the patent office. Because there are 2 distinct examiners involved, the company must manage 2 separate lines of communication. The use of 2 distinct art units further indicates that the pending applications cover different technical classifications within the broader biotechnology field.
VIVLEMORE, TRACY ANN is identified as the busiest examiner, with 1 pending office action. Since the total number of pending actions is 2 and there are 2 distinct examiners, each examiner is handling 1 action. This balanced workload between the 2 distinct examiners means the company must satisfy 2 different officials. The practitioner must address the individual requirements of each examiner while navigating the technical standards of the 2 distinct art units.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VIVLEMORE, TRACY ANN | 1 | 73.0% | +6.4% |
| JOHANSEN, PETER N. | 1 | 59.6% | +24.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18043660 | EXPANDED MEMORY SUBSETS OF GAMMA DELTA T CELLS FOR IMMUNOTHERAPY | VIVLEMORE, TRACY ANN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16901427 | ACTIVATED LYMPHOCYTIC CELLS AND METHODS OF USING THE SAME TO TREAT CANCER AND INFECTIOUS CONDITIONS | JOHANSEN, PETER N. | 3d overdue |
| Art Unit | Apps |
|---|---|
| 1638 | 1 |
| 1644 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18043660 | EXPANDED MEMORY SUBSETS OF GAMMA DELTA T CELLS FOR IMMUNOTHERAPY | VIVLEMORE, TRACY ANN | 1638 | §102§103§112 | Non-Final OA | — | Pending | Mar 01, 2023 |
| 16901427 | ACTIVATED LYMPHOCYTIC CELLS AND METHODS OF USING THE SAME TO TREAT CANCER AND INFECTIOUS CONDITIONS | JOHANSEN, PETER N. | 1644 | §112 | Non-Final OA | 3d overdue | Pending | Jun 15, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSerhat Gumrukcu has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Tracy Ann Vivlemore has the most, with 1 of Serhat Gumrukcu's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
